[{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Juno Therapeutics | Leukemia and Lymphoma Society","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"BCMA-Specific CAR-T Lymphocyte","moa":"B-cell maturation antigen","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fred Hutchinson Cancer Center \/ Juno Therapeutics | Leukemia and Lymphoma Society","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ Juno Therapeutics | Leukemia and Lymphoma Society"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Sonrotoclax","moa":"BCL2","graph1":"Oncology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ BeOne Medicines","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ BeOne Medicines"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"AstraZeneca | Juno Therapeutics | MedImmune | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"JCAR014","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ AstraZeneca | Juno Therapeutics | MedImmune | National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ AstraZeneca | Juno Therapeutics | MedImmune | National Cancer Institute"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Mustang Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fred Hutchinson Cancer Center \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Mustang Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fred Hutchinson Cancer Center \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Mustang Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fred Hutchinson Cancer Center \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Mustang Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"CAR-T Cell","moa":"Chimeric antigen receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Mustang Bio","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ Mustang Bio"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Abemaciclib","moa":"Cyclin-dependent kinase 4 | Cyclin-dependent kinase 6","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ Eli Lilly"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Cyclosporine","moa":"Cyclophilin A","graph1":"Hematology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Incyte Corporation"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Affini-T Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Affini-T Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ Affini-T Therapeutics"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cladribine","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ Pfizer Inc"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"PromiCell Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ PromiCell Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ PromiCell Therapeutics"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ GSK"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Nektar Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Nektar Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ Nektar Therapeutics"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"National Cancer Institute | Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Trabectedin","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ National Cancer Institute | Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ National Cancer Institute | Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Celgene Corporation | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2010","type":"Inapplicable","leadProduct":"Azacitidine","moa":"DNA | DNA (cytosine-5)-methyltransferase 3A | RNA | DNA (cytosine-5)-methyltransferase 1","graph1":"Oncology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Celgene Corporation | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Celgene Corporation | National Cancer Institute"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Immunogen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cytarabine","moa":"DNA polymerase (alpha\/delta\/epsilon) | DNA | RNA","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Immunogen","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ Immunogen"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Cytarabine","moa":"DNA polymerase (alpha\/delta\/epsilon) | DNA | RNA","graph1":"Oncology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Undisclosed"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Fludarabine Phosphate","moa":"DNA polymerase (alpha\/delta\/epsilon) | Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Daunorubicin","moa":"DNA topoisomerase II alpha | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Global Life Technologies Corp.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ethanol","moa":"Gamma-aminobutyric acid receptor subunit alpha-1; Glutamate receptor ionotropic, NMDA 3A; Glycine receptor subunit alpha-1; Glycine receptor subunit alpha-2; Voltage-dependent L-type calcium channel subunit beta-1; 5-hydroxytryptamine receptor 3A; Gamma-aminobutyric acid receptor subunit alpha-2; Neuronal acetylcholine receptor subunit alpha-10; Voltage-dependent L-type calcium channel subunit alpha-1C; Gamma-aminobutyric acid receptor subunit alpha-5; Gamma-aminobutyric acid receptor subunit alpha-4; Gamma-aminobutyric acid receptor subunit alpha-3; Glutamate receptor 1; Voltage-dependent calcium channel gamma-1 subunit; Neuronal acetylcholine receptor subunit alpha-2; Gamma-aminobutyric acid receptor subunit alpha-6; Glutamate receptor 2; Glutamate receptor 4; Glutamate receptor 3; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit beta-2; G protein-activated inward rectifier potassium channel 1; G protein-activated inward rectifier potassium cha","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Swab","sponsorNew":"Fred Hutchinson Cancer Center \/ Global Life Technologies Corp.","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ Global Life Technologies Corp."},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Novartis Pharmaceuticals Corporation | Institute for Prostate Cancer Research (IPCR) | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"18-F Fludeoxyglucose","moa":"Glucose transporter","graph1":"Oncology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Novartis Pharmaceuticals Corporation | Institute for Prostate Cancer Research (IPCR) | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Novartis Pharmaceuticals Corporation | Institute for Prostate Cancer Research (IPCR) | National Cancer Institute"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"National Heart, Lung, and Blood Institute | Rocket Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Filgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ National Heart, Lung, and Blood Institute | Rocket Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ National Heart, Lung, and Blood Institute | Rocket Pharma"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"National Heart, Lung, and Blood Institute | Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ganciclovir","moa":"Human herpesvirus 1 DNA polymerase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ National Heart, Lung, and Blood Institute | Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ National Heart, Lung, and Blood Institute | Genentech"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Simcha Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Interleukin-18","moa":"IL18 Receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Simcha Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ Simcha Therapeutics"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Simcha Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Vevoctadekin","moa":"IL-18 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fred Hutchinson Cancer Center \/ Simcha Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ Simcha Therapeutics"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Incyte Corporation | National Cancer Institute | University of Virginia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Epacadostat","moa":"Indoleamine 2,3-dioxygenase","graph1":"Oncology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Incyte Corporation | National Cancer Institute | University of Virginia","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Incyte Corporation | National Cancer Institute | University of Virginia"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Faron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Faron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ Faron Pharmaceuticals"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Anakinra","moa":"Interleukin-1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"National Cancer Institute | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Deferasirox","moa":"Iron","graph1":"Hematology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ National Cancer Institute | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ National Cancer Institute | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Incyte Corporation"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ Merck & Co"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"SignalOne Bio, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ SignalOne Bio, Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ SignalOne Bio, Inc."},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"EMD Serono | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ EMD Serono | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ EMD Serono | National Cancer Institute"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"National Cancer Institute | EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Avelumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ National Cancer Institute | EMD Serono","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ National Cancer Institute | EMD Serono"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"National Institute on Aging | Gansu Provincial Maternal and Child Health Care Hospital | National Center for Complementary and Integrative Health | Office of Research on Women's Health | Nordic Naturals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fred Hutchinson Cancer Center \/ National Institute on Aging | Gansu Provincial Maternal and Child Health Care Hospital | National Center for Complementary and Integrative Health | Office of Research on Women's Health | Nordic Naturals","highestDevelopmentStatusID":"1","companyTruncated":"Fred Hutchinson Cancer Center \/ National Institute on Aging | Gansu Provincial Maternal and Child Health Care Hospital | National Center for Complementary and Integrative Health | Office of Research on Women's Health | Nordic Naturals"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Incyte Corporation | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2014","type":"Inapplicable","leadProduct":"Allogeneic Hematopoietic Stem Cell Transplant","moa":"Progenitor cell","graph1":"Oncology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Incyte Corporation | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Incyte Corporation | National Cancer Institute"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"medac","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Allogeneic Hematopoietic Stem Cell Transplant","moa":"Progenitor cell","graph1":"Oncology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ medac","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ medac"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Hematopoietic Stem Cell Transplant","moa":"Progenitor cell","graph1":"Oncology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Nohla Therapeutics | National Cancer Institute | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Dilanubicel","moa":"Progenitor cell","graph1":"Oncology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Nohla Therapeutics | National Cancer Institute | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Nohla Therapeutics | National Cancer Institute | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Sanofi"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"ADC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Carmustine","moa":"RNA | DNA | Glutathione reductase","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ ADC Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ ADC Therapeutics"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-directed RNA polymerase L | Replicase polyprotein 1ab","graph1":"Oncology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Gilead Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Gilead Sciences"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Glasdegib","moa":"Smoothened homolog","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ Pfizer Inc"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"National Marrow Donor Program | Vir Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Sotrovimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ National Marrow Donor Program | Vir Biotechnology","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ National Marrow Donor Program | Vir Biotechnology"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Pfizer Inc | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2012","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"Tumor necrosis factor receptor superfamily member 8 | Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Pfizer Inc | National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ Pfizer Inc | National Cancer Institute"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ AstraZeneca"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Acalabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ AstraZeneca"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ Incyte Corporation"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"National Institute on Aging | Gansu Provincial Maternal and Child Health Care Hospital | National Center for Complementary and Integrative Health | Office of Research on Women's Health","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"CAS 50-28-2","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ National Institute on Aging | Gansu Provincial Maternal and Child Health Care Hospital | National Center for Complementary and Integrative Health | Office of Research on Women's Health","highestDevelopmentStatusID":"1","companyTruncated":"Fred Hutchinson Cancer Center \/ National Institute on Aging | Gansu Provincial Maternal and Child Health Care Hospital | National Center for Complementary and Integrative Health | Office of Research on Women's Health"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Juno Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2017","type":"Inapplicable","leadProduct":"Autologous CD19 CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Juno Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ Juno Therapeutics"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"National Cancer Institute | Affini-T Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ Cell","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ National Cancer Institute | Affini-T Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ National Cancer Institute | Affini-T Therapeutics"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Lonza Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Autologous Mesothelin TCR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Lonza Group","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ Lonza Group"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BCG Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ Merck & Co"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"HighPass Bio | PromiCell Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"CD8+ Donor Memory T-cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ HighPass Bio | PromiCell Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ HighPass Bio | PromiCell Therapeutics"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"DVX201","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fred Hutchinson Cancer Center \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"ExCellThera","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"ECT-001-CB","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Juno Therapeutics | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"FCARH143","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Juno Therapeutics | National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ Juno Therapeutics | National Cancer Institute"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"University of Washington | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"HSV529","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ University of Washington | Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ University of Washington | Sanofi"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Takeda Pharmaceutical | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fred Hutchinson Cancer Center \/ Takeda Pharmaceutical | National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Takeda Pharmaceutical | National Cancer Institute"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Amazon","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Neoantigen Peptide Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Amazon","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ Amazon"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Sanaria","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Pfspz Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Fred Hutchinson Cancer Center \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"National Cancer Institute | Horizon Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Recombinant Interferon gamma-1b","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ National Cancer Institute | Horizon Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ National Cancer Institute | Horizon Pharmaceutical"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"National Cancer Institute | Bellicum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"Rivogenlecleucel","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ National Cancer Institute | Bellicum Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Fred Hutchinson Cancer Center \/ National Cancer Institute | Bellicum Pharmaceuticals"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Kineta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Agreement","leadProduct":"KVA12123","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fred Hutchinson Cancer Center \/ Fred Hutchinson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ Fred Hutchinson Cancer Center"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Linvoseltamab","moa":"TNFRSF17","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fred Hutchinson Cancer Center \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Fred Hutchinson Cancer Center \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Fred Hutchinson Cancer Center","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ARQ 531","moa":"BTK","graph1":"Oncology","graph2":"Phase II","graph3":"Fred Hutchinson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fred Hutchinson Cancer Center \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Fred Hutchinson Cancer Center \/ Merck & Co"}]
Find Clinical Drug Pipeline Developments & Deals by Fred Hutchinson Cancer Center
Details :
Nemtabrutinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Details :
Linvoseltamab is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Multiple Myeloma.
Details :
Vevoctadekin is a Protein drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Lymphoma, Large B-Cell, Diffuse.
Details :
Cytarabine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Leukemia.
Details :
Axatilimab is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Bronchiolitis Obliterans Syndrome.
Details :
Sonrotoclax is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Details :
Remdesivir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hematologic Neoplasms.
Details :
Cyclosporine is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anemia, Aplastic.
Details :
Interleukin-18 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.
Details :
MB-106 is a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy. It is being evaluated for the treatment of Waldenstrom macroglobulinemia.
Reset All
